Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy

PloS One
Gina GualanoFabrizio Palmieri

Abstract

Treatment of multi-drug resistant Tuberculosis (MDR-TB) is challenging because it mostly relies on drugs with lower efficacy and greater toxicity than those used for drug-susceptible TB. Aim of the study was to describe the frequency and type of adverse drug reactions in a cohort of MDR-TB patients and their potential impact on treatment outcome. We conducted a retrospective study in a cohort of MDR-TB patients enrolled at a tertiary referral hospital in Italy from January 2008 to December 2016. The records of patients were reviewed for epidemiological, clinical, microbiological and adverse drug reactions data. Seventy-four MDR-TB patients (mean age 32 years, 58.1% males, 2 XDR, 12 pre-XDR TB) were extracted from the Institute data base and included in the retrospective study cohort in the evaluation period (January 2008-December 2016). Median length of treatment duration was 20 months (IQR 14-24). Treatment outcome was successful in 57 patients (77%; 51 cured, 6 treatment completed); one patient died and one failed (2.7% overall); 15 patients were lost to follow-up (20.3%). Sixty-six (89.2%) presented adverse drug reactions during the whole treatment period. Total number of adverse drug reactions registered was 409. Three hund...Continue Reading

References

Feb 28, 2009·The Lancet Infectious Diseases·Evan W OrensteinAlison P Galvani
Apr 13, 2012·The European Respiratory Journal·Giovanni SotgiuGiovanni Battista Migliori
Apr 17, 2014·Annals of the American Thoracic Society·Karthickeyan DuraisamyAjay M V Kumar
Mar 31, 2015·Lancet·Mukund UplekarUNKNOWN for WHO's Global TB Programme
Dec 18, 2015·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Basel KaroWalter Haas
Mar 24, 2017·The European Respiratory Journal·Mayara Lisboa BastosDick Menzies
May 19, 2017·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Yang ZhangSiyan Zhan
Aug 23, 2017·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·H-Y YoonT S Shim
Oct 19, 2017·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·A ReuterJ Furin
Nov 19, 2017·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·A TrébucqH L Rieder
Aug 3, 2018·Seminars in Respiratory and Critical Care Medicine·Charles L Daley, Jose A Caminero
Sep 15, 2018·Lancet·UNKNOWN Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017Dick Menzies

❮ Previous
Next ❯

Citations

Jun 20, 2020·Transactions of the Royal Society of Tropical Medicine and Hygiene·Muhammad AtifSajjad Sarwar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.